^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KANK4-RAF1 fusion

    i
    Other names: KANK4, KN Motif And Ankyrin Repeat Domains 4, ANKRD38, KN Motif And Ankyrin Repeat Domain-Containing Protein 4, Ankyrin Repeat Domain-Containing Protein 38, Ankyrin Repeat Domain 38, KIAA0172, Kidney Ankyrin Repeat-Containing Protein 4, DJ1078M7.1, RAF1, Raf-1 Proto-Oncogene Serine/Threonine Kinase, RAF Proto-Oncogene Serine/Threonine-Protein Kinase, V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1, C-Raf Proto-Oncogene Serine/Threonine Kinase, Proto-Oncogene C-RAF, Raf-1, V-Raf-1 Murine Leukemia Viral Oncogene-Like Protein 1, Raf Proto-Oncogene Serine/Threonine Protein Kinase, Oncogene RAF1, CMD1NN, C-Raf, CRAF, CRaf, NS5, RAF
    Entrez ID:
    5894; 163782
    Related biomarkers:
    Mutation
    CNA
    Fusion
    over1year
    A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850. (PubMed, Oncotarget)
    Combination therapy with riluzole and sorafenib was safe and tolerable in patients with advanced solid tumors. The partial response in a patient with a RAF1 fusion suggests that further exploration in a genomically selected cohort may be warranted.
    P1 data • Journal • Metastases
    |
    KANK4 (KN Motif And Ankyrin Repeat Domains 4) • GRM1 (Glutamate Metabotropic Receptor 1)
    |
    KANK4-RAF1 fusion
    |
    sorafenib • riluzole